contacts Sign In

image

Bottneuro AG

Be the first one to rate! Submit Review

Bottneuro aims to become a leading provider of device based electric stimulation therapies for Alzheimer disease (AD). None of the pharmacological treatments available today slow or stop the progress of this fatal disease. Our NENI® neuromodulation platform technology enables a fast and reliable validation of novel stimulation protocols targeting glial cells which play an important role in the progress of AD. In Switzerland more than 150000 people are affected by AD causing yearly costs of about CHF 10 billion and are a huge burden for the family members as well. We plan to start with clinical trials in 2022 and expect to launch our first product in Switzerland beginning of 2025. We have a strong team with a broad expertise and several years of experience.

Company’s Keywords:

glial cells, alzheimers disease, electrical stimulation, digital therapies, diagnostics

Related Companies：

  1. Avra Medical Robotics, Inc.
  2. SomnoMed Philippines
  3. Directed Light Inc.
  4. Exerion Precision Technology Ulft
  5. Ortocir Ortopedia Cirurgia Ltda
  6. R MED Medical Supplies L.L.C.
  7. Healthware Private Limited
  8. SL Registro de Produtos
  9. Medisafe
  10. Viver Melhor
Q How Many Employees Does This Company Have?

18

Q Which Industry Does This Company Belong To?

medical devices

Q What Is the Annual Income?

Q What Is the Technology of All the Company’s Website?

Google Font API, Nginx, Mobile Friendly, Bootstrap Framework, WordPress.org

Q What Year Was the Company Founded?

2021

Rate us and Write a Review

Your review is recommended to be at least 140 characters long

image

building Own or work here? Claim Now! Claim Now!

Claiming your business Listing

Claim request is processed after verification..

image

image
Doctor
Visit Profile

imageYour request has been submitted successfully.

image